
Please try another search
Shares of Kirby Corporation (NYSE:KEX) have lost 13% against the industry's 16.1% decline in a year’s time. The disappointing performance was caused by weakness in the oil and gas market as well as ramped down activity in coal transportation business.
Let’s discuss the factors hurting the stock.
Dismal performance of the oil and gas market caused a 16% decline in the company’s distribution and services revenues in 2019. The headwind is anticipated to persist in 2020, which is likely to lower revenues at the distribution and services in the range of 12-17%.
Also, reduced activity in coal transportation business is likely to dent coastal revenues (part of the broader marine transportation segment’s revenues) in 2020. Consequently, coastal revenues are anticipated to be either flat or up slightly year over year.
Moreover, the company’s high debt levels are concerning. Evidently, debt to capitalization ratio, a measure of financial leverage, exceeded 28% at the end of fourth quarter, 2019.
Negative Estimate Revisions and Zacks Rank
Investors’ pessimism revolving around the stock is evident from the Zacks Consensus Estimate for 2020 earnings being revised downward by 13.9% in the past 60 days to $3.03.
Kirby carries a Zacks Rank #4 (Sell).
Stocks to Consider
Few better-ranked stocks in the Zacks Transportation sector are Azul S.A (NYSE:AZUL) , Frontline Ltd. (NYSE:FRO) and Costamare Inc. (NYSE:CMRE) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Azul, Frontline and Costamare have moved up 3.6%, 23% and 22.9%, respectively, in a year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Through many years of frustration among gold bugs due to the failure of gold stock prices to leverage the gold prices in a positive way, there were very clear reasons for that...
I know there is the smell of fear in the air when I see my readership double as we reach a point where weekly chart factors come into play. Up until last week, markets have...
• Trump’s trade war, inflation data, and last batch of earnings will be in focus this week. • DoorDash’s imminent inclusion in the S&P 500 is likely to trigger a wave of...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.